Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) along with some other less common diseases generally described by the advanced deterioration of central or peripheral nervous system, structurally or functionally. In the last two decades, mesenchymal stromal cells (MSCs) due to their unique assets encompassing self-renewal, multipotency and accessibility in association with low ethical concern open new frontiers in the context of neurodegenerative diseases therapy. Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages (e.g., neurons, oligodendrocyte, and astrocyte), and thus could be employed to advance cell-based therapeutic strategy. Additionally, as inflammation ordinarily ensues as a local response provoked by microglia in the neurodegenerative diseases, MSCs therapy because of their pronounced immunomodulatory properties is noticed as a rational approach for their treatment. Recently, varied types of studies have been mostly carried out in vitro and rodent models using MSCs upon their procurement from various sources and expansion. The promising results of the studies in rodent models have motivated researchers to design and perform several clinical trials, with a speedily rising number. In the current review, we aim to deliver a brief overview of MSCs sources, expansion strategies, and their immunosuppressive characteristics and discuss credible functional mechanisms exerted by MSCs to treat neurodegenerative disorders, covering AD, PD, ALS, MS, and HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications
Wang, Y., Chen, X., Cao, W., & Shi, Y. (2014) · Nature Immunology · doi:10.1038/ni.3002 · Cited by 1,452
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Sofroniew, M. V. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020420 · Cited by 695
Challenges and Controversies in Human Mesenchymal Stem Cell Therapy
Lukomska, B., Stanaszek, L., Zuba-Surma, E., Legosz, P., Sarzynska, S., & Drela, K. (2019) · Stem Cells International · doi:10.1155/2019/9628536 · Cited by 550
Frenette, P. S., Pinho, S., Lucas, D., & Scheiermann, C. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095919 · Cited by 462
Bai, L., Lennon, D. P., Caplan, A. I., DeChant, A., Hecker, J., Kranso, J., Zaremba, A., & Miller, R. H. (2012) · Nature Neuroscience · doi:10.1038/nn.3109 · Cited by 421
Neuropathology of amyotrophic lateral sclerosis and its variants
Saberi, S., Stauffer, J. E., Schulte, D. J., & Ravits, J. (2015) · Neurologic Clinics · doi:10.1016/j.ncl.2015.07.012 · Cited by 282
Chen, L., Xu, Y., Zhao, J., Zhang, Z., Yang, R., Xie, J., Liu, X., & Qi, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096161 · Cited by 251
Shin, J. Y., Park, H. J., Kim, H. N., Oh, S. H., Bae, J.-S., Ha, H.-J., & Lee, P. H. (2014) · Autophagy · doi:10.4161/auto.26508 · Cited by 243
Lee, J. K., Jin, H. K., & Bae, J.-S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2008.11.059 · Cited by 189
Negi, N., & Griffin, M. D. (2020) · Stem Cells · doi:10.1002/stem.3151 · Cited by 118
Mendes-Pinheiro, B., Anjo, S. I., Manadas, B., Da Silva, J. D., Marote, A., Behie, L. A., Teixeira, F. G., & Salgado, A. J. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00294 · Cited by 103
Somoza, R., Juri, C., Baes, M., Wyneken, U., & Rubio, F. J. (2010) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2010.06.006 · Cited by 72
Cited by
Bian, D., Wu, Y., Song, G., Azizi, R., & Zamani, A. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02697-9 · Cited by 370
Markov, A., Thangavelu, L., Aravindhan, S., Zekiy, A. O., Jarahian, M., Chartrand, M. S., Pathak, Y., Marofi, F., Shamlou, S., & Hassanzadeh, A. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02265-1 · Cited by 257
Self-citationRetractedRegenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview
Sivandzade, F., & Cucullo, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042153 · Cited by 224
“patients suffering from PD were treated with fetal mesencephalic tissue transplantation [10].”
BackgroundGiovannelli, L., Bari, E., Jommi, C., Tartara, F., Armocida, D., Garbossa, D., Cofano, F., Torre, M. L., & Segale, L. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.06.013 · Cited by 102
“As neuronal death, neurodegeneration, neuroinflammation, immune dysfunction, and oxidative stress are common features of NDs (see Table 1), it is not surprising that stem cells, particularly MSCs, have emerged as a promising treatment modality at the forefront of ND research [28,29]; this is especially significant con…”
BackgroundNoorzehi, G., Pasbakhsh, P., Taghizadeh, F., Alikarami, A., Kashani, I. R., & Mojaverrostami, S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118027 · Cited by 3
Metadata
- Authors
- Shariati, A., Nemati, R., Sadeghipour, Y., Yaghoubi, Y., Baghbani, R., Javidi, K., Zamani, M., & Hassanzadeh, A.
- Venue
- European Journal of Cell Biology
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 99
- Issue
- 6
- Pages
- 151097
- ISSN
- 0171-9335 (ISSN-L)
- OpenAlex
- W3037226021
- Cited by
- 92
- References
- 15
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.